SG Tylor
Sharon Barr is appointed executive vice president of biopharmaceuticals R&D by AstraZeneca
Source – AstraZeneca AstraZeneca has made a significant leadership announcement, appointing Sharon Barr as the new Executive Vice President for ...
AbbVie Raises Profit Expectations Despite Q2 Decrease in Humira and Imbruvica Sales
AbbVie executives express satisfaction with the introduction of Humira biosimilars in the US, despite facing significant revenue declines for both ...
Merck’s V116 Vaccine Shows Positive Results in Phase III Trials
Source – Merck Merck, known as MSD outside of the United States and Canada, has announced highly encouraging initial results ...
Teva’s CEO Francis Recruits Angus Grant, Former BeiGene Business Development Head
Teva Pharmaceutical Industries Ltd., the worldās largest maker of generic drugs, has announced the appointment of a new executive to ...
As Vyvanse generics loom, Takeda exaggerates the progress of the dengue vaccine launch
As generics of the popular ADHD medication Vyvanse loom on the horizon, Takeda is looking to rely on newer launches ...
Skyrizi Beats Placebo in Psoriasis Phase 4 Study
Source – Abbvie On July 26, 2023 AbbVie announced the publication of results from the Phase IVĀ IMMpulse study in ...
Sanofi Reports ‘Solid’ Q2 Performance with 3 Ongoing Launches and Dupixent Nearing ā¬10B Milestone
Sanofi, a leading pharmaceutical company, is navigating the challenges posed by the entry of generic versions of its drug Aubagio ...
Pfizer reveals executive leadership to advance its oncology R&D strategy
Source – Pfizer Pfizer has unveiled significant executive leadership changes aimed at advancing its commitment to research and development of ...
Humanigen Struggles Amidst Failed Reverse Merger, Faces Looming Bankruptcy
Three years ago, Humanigen was on a promising trajectory with a COVID-19 therapy in advanced testing and shares valued at ...
Weighing the benefits and drawbacks of the newest Weight loss medication as well as their financial impact
Weight Loss Medication: Obesity rates in the United States have significantly increased since the 1980s, with a staggering 41.9% of ...
NICE is adamant about rejecting a medicine for a rare condition
The UK’s National Institute for Health and Care Excellence (NICE) has issued its final verdict on Clinuvel’s Scenesse, a treatment ...
The UK is looking into GLP-1 medications made by Novo Nordisk, AstraZeneca, Lilly, and Sanofi for GLP-1 inhibitor suicide risk
Following the European Union’s lead, the United Kingdom has initiated an investigation into the potential suicide risks associated with popular ...
Pre-launch KOL conversations may have increased medicine uptake by 1.5 times
Source – Veeva Systems An analysis conducted by Veeva Systems suggests that effective engagement between medical science liaisons (MSLs) and ...
Balfaxar, a warfarin reversal medication from Octapharma, receives FDA approval
Source – Octapharma More than 2.4 million individuals in the United States rely on warfarin, a blood thinner, to prevent ...
After winning the J&J arbitration dispute, Alkermes, which is close to splitting its oncology business, saw a significant Q2 revenue increase
Alkermes is feeling confident about its prospects for the second half of 2023, after winning a big arbitration case against ...
GSK lowers short-term hopes for RSV treatment Arexvy but raises 2023 forecast
Great expectations surround GSK’s entry into the respiratory syncytial virus (RSV) vaccine market with their upcoming shot, Arexvy, set to ...
GSKās Arexvy and Modernaās mRNA-1345 to lead the race for RSV prevention
The respiratory syncytial virus (RSV) is a common cause of respiratory infections, especially in infants and older adults. It can ...
A New Hope for Children and Teens with gMG: Soliris Gets EU Approval
Source – AstraZeneca The European Union (EU) has granted approval for the expanded use of Soliris (eculizumab) to treat refractory ...
Expanding their strategic partnership, AbbVie and Calibr aim to advance a number of preclinical and early-stage clinical assets
Source – AbbVie On July 26, 2023, AbbVie and Calibr announced expanded strategic collaboration to advance several innovative preclinical and ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
Eversana and Amazon are planning an AI-driven drug push
Source – Eversana Eversana and Amazon Web Services (AWS) have formed an alliance to accelerate the adoption of generative artificial ...
With the PeptiDream agreement, Astellas incorporates protein degraders
Source – AstellasĀ Astellas has continued its focus on protein degrader drugs, announcing its second partnership in this category in ...
Jardiance Receives EU Approval for Treating Chronic Kidney Disease (CKD), Posing a Strong Challenge to Forxiga
Source – Boehringer Ingelheim The European Union has granted approval for Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor, Jardiance (empagliflozin), ...
Bayer anticipates a more bleak 2023 as decreased glyphosate sales support the argument for a separation
As calls for a business separation at Bayer grow louder, the company’s weedkiller performance is providing further support for the ...
Tarsus’ Xdemvy is approved by the FDA as the first therapy for common eyelid illness
Source – Tarsus Pharmaceuticals Tarsus Pharmaceuticals has achieved a groundbreaking milestone with the FDA approval of Xdemvy, the first-ever treatment ...
FibroGen CEO Conterno Resigns Amid Roxadustat Launch Setbacks
Source – FibroGen Enrique Conterno, who became FibroGen’s CEO in early 2020, had high hopes for the anemia drug roxadustat ...
Biogen anticipates 1,000 further layoffs by 2025 as it navigates a “transition”
Source – Biogen During the announcement of its first-quarter earnings, Biogen revealed its strategic decision to discontinue the development of ...
Cabometyx patent battle is resolved by Exelixis and Teva with a 2031 generic license
Source – Exelixis Exelixis, the company behind the successful cancer drug Cabometyx, has been actively defending its intellectual property. In ...
Continue to Evaluate TTFields in Pancreatic Cancer in the PANOVA-3 Trial
Source – Novocure The Phase III PANOVA-3 trial, which is assessing Tumor Treating Fields (TTFields) therapy in combination with nab-paclitaxel ...
Magrolimab for myelodysplastic syndromes is discontinued by Gilead
Source – Gilead Science Gilead Sciences has announced the discontinuation of its cancer antibody, magrolimab, in the treatment of blood ...
